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Abstract
The recent development of in vitro hepatitis C virus (HCV) RNA replication systems has provided useful tools for studying the
intracellular anti-HCV activity of ribavirin. Ribavirin has been shown to: (1) induce “error catastrophe” in poliovirus (Crotty et al., 2001,
Proc. Natl. Acad. Sci. USA 98, 6895–6900), (2) be a pseudo-substrate of the HCV RNA-dependent RNA polymerase (RdRp) in vitro (Maag
et al., 2001, J. Biol. Chem. 276, 46094–46098), and (3) increase mutations in HCV RNA in the binary T7 polymerase/HCV cDNA
replication system (Contreras et al., 2002, J. Virol. 76, 8505–8517). These findings have led to the hypothesis that ribavirin may also induce
error catastrophe in HCV. However, the functional relevance of ribavirin-induced HCV RNA mutagenesis is unclear. By use of a colony
formation assay, in which RNA is isolated from the HCV subgenomic replicon system following treatment, the impact of ribavirin,
inosine-5-monophosphate dehydrogenase (IMPDH) inhibitors, and the combination was assessed. Ribavirin reduced HCV replicon
colony-forming efficiency (CFE) in a dose-dependent fashion, suggesting that ribavirin may be misincorporated into replicon RNA and
result in an anti-replicon effect analogous to error catastrophe. This effect was markedly suppressed by addition of exogenous guanosine.
Combination treatment with ribavirin and mycophenolic acid (MPA) or VX-497, both potent, nonnucleoside IMPDH inhibitors, led to a
greatly enhanced anti-replicon effect. This enhancement was reversed by inclusion of guanosine with the treatment. In contrast, MPA or
VX-497 alone had only marginal effects on both the quantity and quality (CFE) of replicon RNA, suggesting that although IMPDH
inhibition is an important contributing factor to the overall ribavirin anti-HCV replicon activity, IMPDH inhibition by itself is not sufficient
to exert an anti-HCV effect. Sequencing data targeting the neo gene segment of the HCV replicon indicated that ribavirin together with MPA
or VX-497 increased the replicon error rate by about two-fold. Taken together these results further suggest that lethal mutagenesis may be
an effective anti-HCV strategy. The colony formation assay provides a useful tool for evaluating mutagenic nucleoside analogs for HCV
therapy. Finally, the data from combination treatment indicate potential therapeutic value for an enhanced anti-HCV effect when using
ribavirin in combination with IMPDH inhibition.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Hepatitis C virus (HCV) infection is a major global
health issue, with an estimated 3% of the world’s population
being chronically infected (Wasley and Alter, 2000).
Among them, about 20–30% eventually progress to chronic
hepatitis, liver cirrhosis, or hepatocellular carcinoma (Alter
and Seeff, 2000). Currently, the standard treatment for HCV
infection involves either interferon- (IFN) or PEG–inter-
feron-, in combination with ribavirin (1--D-ribofurano-
syl-1,2,4-triazole-3-carboxamide) (Fried et al., 2002; Lauer
and Walker, 2001). Ribavirin, when co-administered with
IFN, substantially improves the efficacy of the therapy,
achieving 40% sustained virological response (SVR) in pre-
viously untreated patients, in contrast to 13% with IFN
alone. In relapsed patients who had been treated with IFN
monotherapy, the SVR improvement was even more signif-
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icant (from 5 to 49%) (Davis et al., 1998; McHutchison et
al., 1998). Similarly, the PEG–interferon/ribavirin combi-
nation is significantly better than PEG–interferon alone in
the treatment of chronic HCV infection, with 56% patients
having SVR, versus 29% with PEG-interferon monotherapy
(Fried et al., 2002). However, ribavirin by itself did not have
a significant effect on HCV viremia, despite the fact that it
normalized the serum alanine transaminase (ALT) levels in
a large proportion of patients (Bodenheimer et al., 1997;
Dusheiko et al., 1996).
The underlying mechanism(s) for improvement in SVR
from ribavirin in combination therapy is not yet fully un-
derstood. No pharmacokinetic interactions between IFN
and ribavirin have been detected (Khakoo et al., 1998). Nor
is it clear whether ribavirin itself has any direct anti-HCV
activity due to the lack of an efficient HCV culture system.
Nevertheless, several possible antiviral mechanisms of ac-
tion for ribavirin have been proposed based on findings
from biochemical and virological assays using other RNA
and DNA viral infection models (reviewed in Cameron and
Castro, 2001; Reyes, 2001). To date, ribavirin has been
shown to directly inhibit viral polymerases, such as the
vesicular stomatitis virus (VSV) RNA polymerase (Toltzis
et al., 1988), La Crosse encephalitis virus polymerase
(Cassidy and Patterson, 1989), reovirus transcriptase
(Rankin et al., 1989), influenza virus polymerase (Eriksson
et al., 1977), and HCV RNA polymerase (Z. Hong et al.,
50th American Association for the Study of Liver Diseases,
Dallas, TX, USA, Abstract 773, 1999). A second proposed
mechanism was that ribavirin monophosphate (RMP) acts
as a competitive inhibitor of inosine-5-monophosphate de-
hydrogenase (IMPDH) (Ki 250 nM), a cellular enzyme
involved in the rate-limiting step of the de novo synthesis of
guanine nucleotides (Streeter et al., 1973; Malinowski and
Stollar, 1981). The inhibition of IMPDH by ribavirin led to
a reduction in intracellular guanosine triphosphate (GTP)
pools in Madin–Darby canine kidney (MDCK) cells and
thereby blocked influenza virus replication (Wray et al.,
1985). Support for this mechanism of action also comes
from reversal of ribavirin’s antiviral effect on influenza
virus by exogenous addition of guanosine (Wray et al.,
1985).
More recently, several lines of evidence have suggested
that ribavirin may serve an immunomodulatory role, as an
inducer of the helper-T-cell (CD4) type 1 (Th1) cytokine
response and a suppressor of the type 2 (Th2) cytokine
phenotype (reviewed in Tam et al., 2001)). Although riba-
virin’s immunomodulatory effect may have a role in vivo,
this cannot account for its antiviral activities against a va-
riety of DNA and RNA viruses in cell culture (De Clercq et
al., 1991; Sidwell et al., 1972).
Another recently proposed mechanism of action for riba-
virin is that it may act as a mutagen and push RNA viruses
beyond a critical mutation rate threshold, thereby driving
the virus population into “error catastrophe” (Crotty et al.,
2000). This mechanism is consistent with the observation
that many RNA viruses exist as highly heterogeneous “qua-
sispecies” due to high mutation frequencies (reviewed in
Domingo, 2000). The extremely high error rate of RNA
viruses (due to the low fidelity of the viral replicases) is
proposed to be an evolutionary advantage, but results in a
viral population close to the edge of “error catastrophe,” i.e.,
a small increase in the error rate may lead to a drastic loss
of genome viability/infectivity (Eigen, 1971; Holland et al.,
1990; Domingo, 2000). In support of this theory, Crotty and
co-workers have shown that ribavirin can be incorporated
by the poliovirus-encoded RNA-dependent RNA polymer-
ase into viral transcripts. The incorporated ribavirin is ca-
pable of base pairing equally well with either uridine mono-
phosphate (UMP) or cytidine monophosphate (CMP),
thereby potentially causing transition mutations (Crotty et
al., 2000). It was subsequently shown that the anti-poliovi-
rus activity of ribavirin correlated directly with this muta-
genic effect (Crotty et al., 2001), suggesting that the primary
mechanism of action in this system may be “error catastrophe.”
The contribution of each of the above postulated mech-
anisms to the clinical effect of ribavirin on HCV is still
unknown. Additional support for ribavirin’s action as a
mutagen in HCV therapy comes from a recent report that
ribavirin is a substrate for an engineered form of the RNA-
dependent RNA polymerase (RdRp) (Maag et al., 2001),
and a second study showing that ribavirin treatment resulted
in a two- to four-fold increase in the overall mutation
frequency of HCV RNA in a binary, T7 polymerase-driven
HCV replication system (Contreras et al., 2002). However,
direct evidence for ribavirin-induced error catastrophe in
HCV is still missing, as no viral infection system is avail-
able for measurement of HCV genome infectivity. In the
very closely related HCV surrogate system using GB virus
B (GBV-B), ribavirin treatment led to dramatic reduction in
the infectivity of progeny virions (Lanford et al., 2001).
Moreover, guanosine supplementation and suppression of
intracellular guanosine pools by mycophenolic acid (MPA),
a potent uncompetitive IMPDH inhibitor (Ki10 nM) (Carr
et al., 1993), have been shown to suppress and enhance,
respectively, the effect of ribavirin despite the fact that
neither alone had any effect on virus replication (Lanford et
al., 2001).
In this report, the recently developed HCV subgenomic
replicon system (Lohmann et al., 1999; Blight et al., 2000) has
been used to examine ribavirin’s in vitro anti-HCV effect and
possible underlying mechanisms of action (MOAs).
Results
Effect of ribavirin on HCV replicon copy number
Taking advantage of the recently developed HCV sub-
genomic replicon system, initial studies examined whether
ribavirin would decrease replication. The replicon-bearing
cells were treated with various concentrations of ribavirin
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(0, 0.16, 0.63, 2.5, 10, 40, 160, and 640 M) in a 96-well
plate format. Three days later the level of replicon RNA was
determined by real-time RT-PCR, using GAPDH as a con-
trol for cellular RNA (Fig. 1). Ribavirin appeared to reduce
the HCV replicon copy number in a dose-dependent man-
ner, with an EC50 of 80 M and an EC90 of 640 M
(Fig. 1). However, this anti-replicon activity closely corre-
lated, or overlapped, with the cytotoxicity profile of the
compound. The inhibitory effect of ribavirin in this replicon
system is reproducible, but indicates a very narrow thera-
peutic window between activity and cellular toxicity. Cyto-
toxicity of ribavirin was evaluated in two ways: MTS assay
and reduction in cellular GAPDH RNA as measured by
real-time PCR. Fifty percent cytotoxicity concentration, or
CC50, was 200 M ribavirin as estimated by GAPDH
reduction and 640 M by MTS assay (Fig. 1). This
difference suggested that ribavirin is a cytostatic but not a
cytotoxic agent. Replicon cells that have undergone high-
dose ribavirin treatment (100 M) are morphologically
larger than untreated cells and grow more slowly (e.g., 200
M ribavirin treatment for 2 weeks resulted in a five-fold
increase in the cell doubling time from 21 to 100 hours,
data not shown). These cells regained their normal growth
rate on removal of ribavirin from the culture medium (data
not shown).
Although a small therapeutic window appears to exist for
ribavirin, based on replicon copy number in this system, it
is important to note that replicon replication strongly cor-
relates with host cell metabolic status (Pietschmann et al.,
2001). Ribavirin’s cytostatic activity may therefore compro-
mise reduction in replicon copy number as an in vitro
measurement of drug efficacy due to the global inhibition of
cellular metabolism. The observation that ribavirin has only
weak anti-HCV replicon activity in vitro is consistent with
clinical data from ribavirin monotherapy indicating no sig-
nificant impact on HCV viral load in serum (Lauer and
Walker, 2001).
Ribavirin reduces the colony-forming efficiency of HCV
replicon RNA
In an effort to evaluate the anti-replicon activity of riba-
virin independent of its cytostatic effect, colony formation
experiments (analogous to reinfection studies) were per-
formed. Following treatment of replicon cells with ribavirin
in G418-free medium for 10 days, the total cellular RNA
(including replicon RNA) was extracted and used to trans-
fect naı¨ve Huh7 cells. Three weeks later, the G418-resistant
colonies were counted and normalized to the replicon copy
number in the input RNA, which had been determined by
real-time PCR using an HCV replicon standard curve, to
obtain the colony-forming efficiency (CFE). [Integrity of
the replicon RNA recovered from these treatments was
confirmed by performing qPCR targeting the 5 UTR, neo,
NS3, and NS5B regions, respectively. The data (not shown)
yielded comparable quantification suggesting no significant
degradation of replicon RNA had occurred.] As retransfec-
tion involves only RNA, and not any associated viral or host
proteins, CFE is a direct assessment of the viability (repli-
cative integrity) of the input replicon genomes.
To control for transfection efficiency, the same amount
of total RNA (8 g) was used in each transfection. The
linear range of input genome RNA—for obtaining similar
CFE—was determined by serially diluting replicon RNA
from untreated cells with Huh7 RNA (1:1, 1:4, and 1:16).
RNA diluted 1:4 (from 80 million to 20 million replicon
copies) did not change CFE significantly; the 1:16 dilution
(from 80 million to 5 million replicon copies) reduced CFE
approximately fourfold (data not shown), suggesting a lin-
ear range between 20 and 80 million genome copies/trans-
fection. About 580 colonies were obtained from 80 million
copies wild-type HCV replicon RNA, giving a CFE of
approximately 106 colonies/g of replicon RNA which is
comparable to previous reports (Krieger et al., 2001).
Ribavirin reduced the replicon RNA’s ability to generate
G418-resistant colonies in a dose-dependent manner: 50
M ribavirin reduced CFE by 2-fold, 100 M ribavirin
reduced CFE by 4-fold, and 300 M ribavirin reduced
CFE by24-fold (Fig. 2). Ribavirin at 10 M did not result
in a statistically significant change in CFE (Fig. 2). These
data suggested that ribavirin at, or above, 50 M caused a
statistically significant reduction in the HCV replicon qual-
ity (Table 1). In these experiments, up to the 100 M
treatment, the input replicon RNA varied only within a
2-fold range (Fig. 2, top row), ensuring that the difference in
CFE was not an artifact of input copy number. With the 300
M ribavirin treatment, the replicon copy number dropped
11-fold (to 7 million); however the CFE reduction (24-fold)
was still significant even allowing for the 4-fold drop in
transfection efficiency predicted by the wild-type genome
titration study (i.e., an additional 6-fold reduction was still
observed). It is noteworthy that replicon cells treated with
up to 100 M ribavirin for up to 10 days still showed only
marginal reduction of replicon copy number (less than
Fig. 1. Effect of ribavirin on HCV replicon copy number and cytotoxicity.
Replicon cells were treated with various concentrations of ribavirin (0–640
M) for 3 days. Levels of cellular GAPDH RNA and HCV replicon RNA
were determined by real-time (Taqman) RT-PCR (see Materials and meth-
ods). The amounts of cellular GAPDH RNA (squares), replicon RNA
(triangles), and cell viability (open circles, as determined by the MTS
assay) following ribavirin treatment were plotted as percentages of no drug
controls. (The leftmost point on the x axis corresponds to 0 M ribavirin.)
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2-fold) (Fig. 2), consistent with the data from the 3-day
dosing experiments (Fig. 1).
Exogenous guanosine suppresses ribavirin’s anti-replicon
activity
Ribavirin and its monophosphate metabolite RMP have
been shown to directly inhibit cellular IMPDH and decrease
the intracellular pools of GTP (Wray et al., 1985). One
explanation for the observed reduction in replicon CFE by
ribavirin is that ribavirin, being a guanosine analog, may be
misincorporated into the replicon genome; to do so, ribavi-
rin must compete with cellular GTP. To test whether a
decrease in GTP pool (induced by ribavirin) contributes to
the replicon CFE reduction, exogenous guanosine, which
would replenish GTP pools via the salvage pathway, was
co-administered with ribavirin. As shown in Fig. 3, 10 M
exogenous guanosine ( 30- or 100-fold excess of physio-
logical GTP levels within HepG2 and MDCK cells, respec-
tively (Z. Hong et al., unpublished data; Wray et al., 1985))
appeared to partially relieve the ribavirin-induced CFE re-
duction (from 200 to 440; no drug control, 730). Addition of
10 M adenosine had no effect (Fig. 3). These data sug-
gested that IMPDH inhibition and subsequent lowering of
GTP pools may contribute to the observed reduction in
CFE. The observation that addition of guanosine failed to
completely reverse ribavirin’s adverse effect on CFE further
suggested that the reduction of the GTP pool alone cannot
account for all of the observed anti-replicon activity.
Neither MPA nor VX-497 alone has any effect on
replicon RNA level and only a modest effect on CFE
To further address whether IMPDH inhibition (i.e., re-
duction of GTP pools alone) is sufficient to reduce replicon
RNA copy number and CFE, two specific IMPDH inhibi-
tors, mycophenolic acid (MPA) (Ki 20 nM) (Carr et al.,
1993), and VX-497 (Ki 10 nM) (Markland et al., 2000),
were evaluated for their anti-replicon effect. Replicon cells
were treated with various concentrations of MPA (0–40
M), but no significant effect on replicon quantity was
observed (Fig. 4A), even though MPA began to show ob-
vious cytotoxicity above 2 M (data not shown). Similarly,
VX-497, from 10 nM to 10 M, did not inhibit replication
(Fig. 4B). The EC50 of VX-497 against a variety of RNA
viruses including BVDV and EMCV ranges from 1 to 12
M in tissue culture (Markland et al., 2000). VX-497 at
concentrations above 10 M showed significant cytotoxic-
ity to replicon-bearing Huh-7 cells (data not shown). The
effect of MPA and VX-497 on replicon CFE was examined
by RNA retransfection assays. As shown in Fig. 5, 2 M
MPA (100  Ki, the highest tolerated dose for the 10-day
assay) reduced replicon CFE only minimally (2-fold), and
as in the 3-day assay MPA did not reduce the total replicon
copy number (Fig. 5, bottom, and Table 1). Similarly, VX-
497 (100 nM, 10  Ki) by itself, reduced the replicon
CFE by only2-fold, without having any effect on the copy
number (Fig. 6, middle). These data suggest that IMPDH
inhibition and reduction of cellular GTP pools alone have
only modest effects on CFE.
Fig. 2. Ribavirin reduces the colony formation efficiency of the HCV
replicon. Replicon cells were treated with 0, 10, 50, 100, or 300 M
ribavirin for 10 days in the absence of G418 selection. Replicon RNA was
then extracted and used to transfect naı¨ve Huh7 cells followed by G418
selection (see Materials and methods). The input replicon RNA copy
number, presented in the first row of each panel, was independently
determined by real-time RT-PCR using an HCV replicon RNA standard
curve. Total number of colonies is presented in the second row of each
panel. Colony formation efficiency (colony number normalized by HCV
copy number) is given in the third row. R, ribavirin.
Table 1
Reduction in HCV subgenomic replicon CFE induced
by different treatments
Treatment Fold reduction
in CFEa
N Pb
No drug 1 5 —
10 M Rbv 1  0.2 5 0.2
50 M Rbv 2  0.2 5 0.05
100 M Rbv 4  0.6 5 0.05
300 M Rbv 20  6 3 0.05
2 M MPA 2  0.3 3 0.05
2 M MPA  10 M Rbv 4  0.7 3 0.05
2 M MPA  100 M Rbv 20  4 3 0.05
0.1 M VX-497 2  0.1 3 0.05
0.1 M VX-497  10 M Rbv 5  2 3 0.05
0.1 M VX-497  100 M Rbv 19  8 3 0.05
a Values are means  SD. CFE, colony-forming efficiency.
b Based on pairwise two-tailed t test, using average tabled t value for
both.
Fig. 3. Exogenous guanosine, but not adenosine, markedly reduced riba-
virin’s effect on replicon viability. Replicon cells were treated with riba-
virin (“R”) alone or in combination with guanosine (“G”) or adenosine
(“A”) for 10 days, at the concentrations indicated. The RNA from these
cells was prepared and transfected into Huh-7 cells to measure the specific
colony formation efficiency as described under Materials and methods.
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Reduction of CFE by ribavirin is enhanced by IMPDH
inhibitors
Reasoning that if ribavirin was incorporated at all into
the replicon genome it must compete with intracellular GTP
(Maag et al., 2001), IMPDH inhibitors were co-adminis-
tered with ribavirin in an effort to facilitate its incorporation.
Replicon cells were treated with a combination of ribavirin
and either MPA (Fig. 5) or VX-497 (Fig. 6). MPA at 2 M
greatly potentiated the effect of ribavirin on replicon CFE:
the reduction in CFE was promoted from 1- to 4-fold with
10 M ribavirin, and from 4- to 20-fold with 100 M
ribavirin, compared with ribavirin monotreatment (P 
0.05) (Fig. 5, Table 1). The effects from combination treat-
ments were also significantly higher than that from MPA
treatment alone (P  0.05) (Table 1).
This enhancement phenomenon was confirmed by re-
placing MPA with VX-497. The VX-497/ribavirin combi-
nation dramatically reduced the CFE of the replicon by up
to 20 fold, in contrast to ribavirin (4-fold, P  0.05) or
VX-497 (2-fold, P  0.05) alone (Fig. 6, middle, and Table
1). The reduction in CFE with combination treatment was
evident even with 10 M ribavirin (4-fold reduction in
CFE). Consistent with the MPA data, the replicon copy
number from the VX-497/ribavirin 10-day treatment was
reduced only 1- to 3-fold (Fig. 6, middle).
To further confirm the reduction of cellular GTP levels
as the underlying mechanism for the observed enhance-
ment, 10 M guanosine was added to the ribavirin/VX-497
dosing regimen. As shown at the bottom of Fig. 6, exoge-
nous guanosine restored the colony-forming ability to wild-
type level. (Combining the outcome from the two indepen-
dent studies yields an apparent CFE level 0.9  0.3 that of
the wild-type.) These data, as well as those from MPA/
ribavirin treatment, suggest that the activity of ribavirin on
replicon quality (CFE) could be enhanced by co-adminis-
tration of IMPDH inhibitors.
Ribavirin/IMPDH inhibitor combination increases
mutation frequency in replicon neo gene
To determine whether ribavirin, IMPDH inhibitors, or a
combination, can increase the mutation frequency of the
replicon genome, the sequences of the NS5A and neo genes,
before and after drug treatment, were analyzed by extracting
replicon RNA and PCR amplifying/cloning the target into
the bacterial vector. Inserts from independent bacterial col-
onies were sequenced and analyzed for mutation frequency.
The effects of ribavirin (100 M), MPA (2 M), and
VX-497 (0.1 M) on mutation of either the NS5A or neo
gene were not statistically significant (Table 2 and Table 3);
Fig. 5. Ribavirin’s anti-replicon activity is potentiated by MPA. Replicon
cells were treated with ribavirin (“Rbv”) alone (top) or in combination with
2 M MPA (bottom) for 10 days in the absence of G418 selection. The
RNA from these cells was prepared and transfected into Huh-7 cells to
measure the specific colony formation efficiency as described under Ma-
terials and methods. The CFE results from 2 M MPA treatment were
included in the lower panel for comparison.
Fig. 4. Neither MPA nor VX-497 significantly reduces the copy number of
the HCV replicon. (A) MPA (0–40 M) was applied to replicon cells and
the viral RNA level, after normalization against cellular GAPDH, is shown
as a percentage of the no drug control on the y axis. (B) Replicon cells were
treated with VX-497 (0–10 M) for 3 days followed by Taqman measure-
ment of the HCV replicon and cellular GAPDH RNA. Viral RNA levels,
after normalization against GAPDH, are shown as percentages of the no
drug control.
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however, the ribavirin/MPA and ribavirin/VX-497 combi-
nations did result in a statistically significant increase in the
mutation frequency of the neo gene by 2.0- and 2.3-fold,
respectively (P  0.05) (Table 3) . In contrast, no statisti-
cally significant change was seen in the NS5A gene (Table
2). Consistent with the observation that ribavirin forms base
-pairs with either cytidine or uridine (Maag et al., 2001), the
vast majority of the nucleotide mutations seen in the riba-
virin- and combination-treated replicons were transitions
(89%). Moreover, ribavirin-induced mutations seem to be
randomly distributed in the NS5A and neo fragments with
no apparent mutational “hotspots” (data not shown).
Discussion
The development of the HCV subgenomic replicon (Lo-
hmann et al., 1999) (Blight et al., 2000), in addition to the
binary HCV full-length replication system (Chung et al.,
2001), has allowed for the first time a detailed study of the
mechanisms of action underlying ribavirin’s intracellular
anti-HCV activity. The effect of ribavirin on the HCV
subgenomic replicon has been examined in two ways: by
measuring the HCV replicon copy number (quantity) using
quantitative real-time RT-PCR; and by assessing the colony
formation efficiency (quality) of the replicon RNA by trans-
fection assays. Treatment with ribavirin at, or below, cyto-
toxic levels (50 M) for up to 10 days had only minimal
effects on intracellular replicon RNA level (Figs. 1, 2, 6),
consistent with the clinical observation that ribavirin mono-
therapy is not effective in reducing HCV viremia (Lauer and
Walker, 2001). Higher concentrations of ribavirin consid-
erably lowered the HCV replicon RNA level; however, a
clear conclusion is difficult to draw as this effect may
largely result from the cytostatic effect of ribavirin. The
effect of ribavirin on the CFE of the replicon RNA seemed
to be more pronounced, with 50 M ribavirin reproducibly
decreasing the replicon CFE by about 2-fold, and higher
doses decreasing it up to 20-fold (Fig. 2, Table 1). More-
over, by separating drug treatment from readout, the colony
formation assay makes possible evaluation of high levels of
drug without obfuscation by the cytotoxicity issue. Without
a true HCV culture system this approach may be the best
surrogate for assessing the impact of mutagens on viral
“infectivity.”
Fig. 6. Co-administration of VX-497 enhances ribavirin’s effect on repli-
con CFE and the enhancing effect is reversed by exogenous guanosine.
Replicon cells were treated with ribavirin (“R”) alone (top) or together with
100 nM VX-497 (middle), or in combination with 100 nM VX-497 and 10
M guanosine, for 10 days in the absence of G418 selection (bottom). The
RNA from treated replicon cells was extracted and transfected into Huh-7
cells to measure the specific colony formation efficiency. *Data represent
averages of two independent studies.
Table 2
Mutation frequency of the HCV replicon NS5A gene
from different treatment
Treatment NS5A mutation rate
(103)a
N Pb
No drug 6  2 16 —
100 M Rbv 7  2 15 0.1
300 M Rbv 8  2 9 0.05
2 M MPA 7  2 13 0.1
2 M MPA  100 M Rbv 9  4 7 0.05
0.1 M VX-497 7  2 5 0.2
0.1 M VX-497  100 M Rbv 7  2 9 0.2
a Values are means  SD.
b Based on pairwise two-tailed t test, using average tabled t value for
both.
Table 3
Mutation frequency of the HCV replicon neo gene
from different treatment
Treatment neo mutation rate
(103)a
N Pb
No drug 4  4 24 —
100 M Rbv 7  4 8 0.1
2 M MPA 6  3 10 0.2
2 M MPA  100 M Rbv 8  5 10 0.05
0.1 M VX-497 4  4 13 0.2
0.1 M VX-497  100 M Rbv 9  4 7 0.05
a Values are means  SD.
b Based on pairwise two-tailed t test, using average tabled t value for
both.
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While confirming in principle the results of Chung et al.
(i.e., that ribavirin leads to mutations in the HCV genome)
(Contreras et al., 2002), these studies differ in several as-
pects and offer several additional insights into ribavirin’s
mechanism of action. First, the subgenomic system used in
this study may be more comparable to true HCV replication,
as the replicon RNA comes solely from autonomous repli-
cation based on the RdRp; that is, the interpretation of the
data is not complicated by the involvement of a second
DNA-dependent RNA polymerase (i.e., the T7 RNA poly-
merase) as in the binary T7/HCV DNA viral replication
system. Furthermore, the replicon-bearing cells can be cul-
tured virtually indefinitely, rendering flexibility of drug
treatment duration, whereas dosing and drug exposure in the
binary HCV replication system are limited, as the host cells
must be harvested 24 h after T7 polymerase delivery, due to
the cytopathic effect of the vaccinia viral vector (Chung et
al., 2001). Second, since the tolerability of the HCV genome
to enhanced mutation rates (i.e, the “error threshold”) is
unknown, the ribavirin mutagenesis data alone do not pro-
vide an answer to whether the increase in mutation rate
would affect HCV RNA function. In contrast, the colony
formation assay measures the ability of the HCV replicon
RNA to de novo generate viable G418-resistant colonies in
transfected Huh-7 cells, thereby linking ribavirin treatment
to the functionality of the progeny HCV RNA. Third, in
these experiments the effect of ribavirin on replicon CFE
was dose-dependent while in the binary system there was no
dose response of induced mutation frequencies (Contreras et
al., 2002). Finally, while the studies with the binary HCV
replication system focused on the mutagenic activity of
ribavirin, the current studies underscore the importance of
intracellular GTP pools in regulating the ribavirin anti-HCV
replicon activity.
Recently Lanford et al., (2003) have described observa-
tions similar to ours in their hepatitis C subgenomic replicon
system. The reductions in replicon quantity from ribavirin
were comparable to the results reported above (e.g., 2- to
15-fold reduction using 100–160 M in this study vs a 2- to
19-fold reduction using 100–200 M). Lanford and col-
leagues also indicated complete abrogation of colony for-
mation following 400 M treatment for 72 h (while in this
study no colonies were observed following 500 M treat-
ment after 10 days). One notable difference between the two
studies was the apparent lack of cytotoxicity in the Lanford
et al. report (i.e., no toxicity at 400 M, 9 days whereas
cellular toxicity was demonstrated in this study even at 100
M, 10 days). The use of confluent replicon cultures by
Lanford et al. to evaluate the cytotoxicity of ribavirin
greatly reduces the apparent toxicity, something observed in
the course of these studies as well (data not shown).
The recent demonstration that ribavirin induces “error
catastrophe” of poliovirus by Crotty et al. (2001) has drawn
extensive interest among investigators. In support of this
theory, ribavirin has been shown by in vitro biochemical
assays to be a pseudo-substrate of the HCV RdRp and to
pair equally with either UMP or CMP (Maag et al., 2001).
Subsequently, Contreras et al. reported that ribavirin in-
creases the overall mutation rate of the HCV RNA in the
binary HCV replication system (Contreras et al., 2002).
These reports have led to a hypothesis that ribavirin may be
incorporated into the HCV genome, mutagenize the prog-
eny RNA, and induce “error catastrophe” in HCV. This
report presents evidence for ribavirin-induced loss of colo-
ny-forming efficiency in HCV replicon. Does it provide
direct support for the theory of “error catastrophe” in HCV
ex vivo? Unfortunately, even though treatment with very
high doses of ribavirin ( 500 M) did result in complete
loss of colony formation in one “infection”/transfection
cycle (data not shown), it is not possible to determine
whether this effect was replicon-based or due largely to
cellular toxicity. The multiple rounds of “infection” needed
to demonstrate “viral eradication” are not practical with
replicon transfection, as it takes more than 1 month for each
round of transfection/colony formation and expansion.
Moreover, unlike the viral infection assay, the CFE exper-
iment is limited by the relatively narrow linear range of
input replicon RNA, making it difficult to use recovered
RNA from high-dose ribavirin treatments in the assay, as
the replicon RNA yield would be too low.
In these studies a 10-day treatment of replicon cells with
100 M ribavirin reduced the intracellular viral transcript
level only by 40% (Fig. 2). Likewise ribavirin/MPA or
ribavirin/VX-497 combination treatment reduced replicon
copy number only 50 to 70% even though the replicon CFE
was dropped 20- to 25-fold (Figs. 5, 6). In poliovirus stud-
ies, while the virus plaque-forming unit (PFU) (infectivity)
was decreased 18- to 140-fold by ribavirin, the amount of
viral RNA was reduced by only 6- to 16-fold (Crotty et al.,
2001). The reason for the differential impact of ribavirin on
the quantity and quality of the genetic material of poliovirus
and HCV replicon is unclear. It would be of interest to
determine whether true HCV infectivity following ribavirin
treatment is changed in vivo, when a robust HCV culture
system becomes available.
The nucleoside analog-induced loss of viral infectivity
has been shown to parallel moderate increases in mutation
frequency in several studies (Loeb et al., 1999; Sierra et al.,
2000; Pariente et al., 2001; Crotty et al., 2001). The NS5A
and neo genes of the replicon showed different susceptibil-
ity to the mutagenic effects of ribavirin, with and without
IMPDH inhibitors. Although the NS5A gene mutation fre-
quency seemed to increase slightly by these treatments, the
differences were not statistically significant except for that
from the 300 M ribavirin treatment (Table 2). In contrast,
the neo gene was mutated to a greater extent, with the
combination treatments yielding statistically significantly
increases in the error rate (2-fold, P  0.05) (Table 3).
Since there was no G418 (neomycin) selection pressure
during the treatment, the differential impact of the drugs on
the mutation rates of the NS5A and neo genes may have
been due to the total absence of selection pressure on the
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antibiotic resistance gene; that is, replicon RNA bearing a
defective NS5A gene may have been selected against during
treatment whereas replicon RNA with a mutated neo frag-
ment may have had no deleterious effect. Alternatively, as
Grande-Perez et al. have recently reported in lymphocytic
choriomeningitis virus (LCMV) infection system, the mu-
tagenesis extinction by 5-fluorouracil does not correlate
linearly with the increase in the viral genome mutation
frequency; and the mutations were not evenly distributed
throughout the virus genome (Grande-Perez et al., 2002).
Therefore the detailed molecular mechanism for nucleoside-
driven virus “error catastrophe” may be complex. Further
sequencing analysis, targeting other replicon regions, is
needed to determine whether the reduction in replicon CFE
correlates more directly with the increase in the mutation
rate of a particular region of the HCV replicon.
A second possible explanation for the lack of simple
correlation between observed mutation frequency and drop
in infectivity is that the replicon error rate is already so high
that it may mask small increases induced by ribavirin (com-
pare the mutation rate of the untreated replicon genomes
maintained in the absence of G418 for 10 days (4–6 
103) (Tables 2, 3) with that of the binary HCV system (9
 105) (Contreras et al., 2002) or the VP1 gene of the
poliovirus (1.5 104) (Crotty et al., 2001). The reason for
this high apparent mutation frequency of the replicon ge-
nome is unclear. Comparable amplification/cloning/se-
quencing strategies employed by others (Contreras et al.,
2002, i.e., amplification of 1–2 g of cellular RNA, 35–40
cycles, followed by cloning and DNA template preparation
for sequencing) have yielded significantly lower mutation
frequencies (see above), suggesting that this high error rate
is an authentic property of the replicon system. Another
possibility is that the low level of ribavirin misincorpora-
tion, although not significantly increasing the overall muta-
tion of the HCV genome, can dramatically impact the func-
tion of viral genomes by either changing certain RNA
secondary and tertiary structures important for HCV func-
tion (such as stem-loops in the 3 and 5 UTRs and/or the
IRES) and/or by hampering the HCV translational process
by disrupting codon–anticodon recognition (Cameron and
Castro, 2001). More studies are needed to fully address
these possibilities.
The role of IMPDH inhibition in the ribavirin antiviral
effect was also examined. The current studies suggest that
exogenous guanosine suppressed the ribavirin effect on
CFE and potent IMPDH inhibitors such as MPA and VX-
497 enhanced this effect (Figs. 5, 6). The logical inference
is that IMPDH inhibition contributes to ribavirin’s anti-
HCV activity by reducing the competition with intracellular
GTP for incorporation into nascent replicon genomes. The
fact that MPA or VX-497 alone had only minimal effect on
both the quantity and the quality of the HCV replicon
suggests that IMPDH inhibition alone may not be the pri-
mary mechanism by which ribavirin inhibits HCV in vivo.
Whether the ability of ribavirin to reduce the replicon
CFE plays a role in the clinical treatment of HCV is not
clear. The peak concentration of ribavirin in patients’ serum
is 3 to 17 M and higher dosing is usually limited by
hemolysis and decreased red blood cell count (Glue, 1999;
Preston et al., 1999), whereas in these studies, reduction in
replicon CFE was not obvious below 50 M. Ribavirin at
clinically relevant doses (e.g., 10 M) did not appear to
affect either the copy number or the CFE of the replicon,
agreeing with clinical data that ribavirin monotherapy is not
effective in reducing HCV viral load in serum (Dusheiko et
al., 1996). Although some accumulation of ribavirin may
occur in the liver (Glue, 1999), it is unclear if the achievable
intracellular drug concentration is sufficient to exert a major
mutagenic effect on HCV in patients. As the ribavirin/
IMPDH inhibitor combination did not incur additional cy-
totoxicity to Huh-7 cells (data not shown), these studies
suggest that combination treatment may have potential clin-
ical value, by eliciting enhanced anti-HCV effect at clini-
cally tolerable ribavirin doses. Further clinical studies are
needed to address the therapeutic relevance of this ap-
proach.
Materials and methods
Compounds
Ribavirin (1--D-ribofuranosyl-1,2,4-trizole-3-carbox-
imide) was obtained from Schering–Plough Research Insti-
tute (SPRI) and was stored frozen as a 20 mM stock solution
in phosphate-buffered saline (PBS). Mycophenolic acid
(MPA) and guanosine were both purchased from Sigma
(Catalog Nos. M3536 and G6264, respectively) and were
stored frozen in dimethyl sulfoxide (DMSO) as 20 mM
stock solutions. VX-497 was synthesized at SPRI as de-
scribed (Markland et al., 2000) and was stored frozen in
DMSO as 20 mM stock solutions.
Cell cultures
Human hepatoma cell line Huh-7 cells were grown in
Dulbecco’s modified minimal essential medium (DMEM,
Cellgro) supplemented with 10% fetal bovine serum, 4 mM
L-glutamine, nonessential amino acids, 10 mM Hepes,
0.075% sodium bicarbonate, 100 U/ml penicillin, 100
g/ml streptomycin, and 1 mM sodium pyruvate. HCV
subgenomic replicon (containing NS5A S1179I adaptive
mutation) was constructed at SPRI in a manner similar to
that previously reported (Lohmann et al., 1999) and was
identical in sequence to the “S1179I” replicon reported by
Blight et al., (2000) The replicon-bearing Huh-7 cells were
maintained in the Huh-7 medium (described above) supple-
mented with 1 mg/ml G418 (Geneticin, Gibco-BRL).
340 S. Zhou et al. / Virology 310 (2003) 333–342
RNA quantification by real-time RT-PCR (“Taqman”)
assays
Replicon cells were seeded at 3000 cells per well in
96-well Bio-coated plates (Becton Dickinson) and allowed
to adhere overnight. The culture medium was replaced with
5% serum medium containing the experimental compound
the next day. Seventy-two hours later the plates were har-
vested by aspirating medium, washing twice with PBS, and
adding in 30 l cell lysis buffer (Ambion, Catalog No.
8721). The plates were then heated at 75°C for 5 min
followed by freezing at 70°C for 10 min. The cell lysate
was assayed for HCV replicon copies by one-step real-time
RT-PCR (“Taqman”) assays using the ABI 7700 instru-
ment. More specifically, replicon RNA in the cell lysate was
reverse-transcribed into cDNA, which then served as a tem-
plate for the real-time PCRs. The amount of cDNA template
(which correlates with the replicon copy number in the
original cell lysate) was determined by the PCR cycle num-
ber (“Ct”) at which a threshold level of PCR product is
generated. The primers used to monitor the HCV NS5B
gene were (forward) ATGGACAGGCGCCCTGA and (re-
verse) TTGATGGGCAGCTTGGTTTC. The double-fluo-
rescence-labeled probe (CACGCCATGCGCTGCGG) was
purchased from Applied Biosystems (Part No. P6448-
6464). Cellular GAPDH (glyceraldehyde 3-phosphate de-
hydrogenase) mRNA from same cell lysate was used as an
internal control for cell number and metabolic status (prim-
ers/probes purchased from Perkin–Elmer, Part No.
4310859). Every assay was carried out in triplicate and each
study was independently performed at least two times. The
results were graphed using mean values from a representa-
tive study.
Cytotoxicity determination
Cytotoxicity of a given drug or combination of drugs was
determined by two methods: MTS assay using the com-
pound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (CellTiter 96
Aqueous One Solution cell proliferation assay, Promega,
Part No. TB245) following manufacturer’s instructions and
by quantification of cellular GAPDH RNA using quantita-
tive real-time RT-PCR as described above.
Replicon RNA colony formation efficiency assay
Replicon cells were treated with compound(s) for 10
days in complete DMEM (without G418), with the medium/
compound being changed every 2–3 days. Total cytoplas-
mic RNA was extracted using the RNA Easy Kit from
Qiagen (Catalog No. 74104) and the RNA concentration
determined by absorbance at 260 nm. HCV replicon copy
number in each RNA sample was determined by real-time
RT-PCR using a replicon RNA-standard curve. Eight mi-
crogram of total RNA suspended in 50 l PBS was mixed
with 50 l cell suspension (2  106 Huh-7 cells in PBS in
a 0.1-cm electroporation cuvette; Bio-Rad, Catalog No.
165-2089). After two pulses at 960 F and 350 V using the
Gene Pulser System (Bio-Rad), cells were immediately
transferred to 10 ml of complete DMEM medium (without
G418) and seeded onto 10-cm culture dishes. After 24 h,
medium was replaced by complete DMEM with 0.5 mg/ml
G418. The G418-containing medium was changed every
2–3 days. Three weeks later, colonies were counted follow-
ing staining with crystal violet (0.5 g/liter in 30% methanol,
3.2% formaldehyde). Representative results of multiple
(2) independent transfections are shown.
Cloning and sequencing of replicon RNA
Total cytoplasmic RNA was isolated from compound-
treated replicon cells and used as a template for amplifica-
tion of NS5A region (positions 5077 to 6417 of the HCV 1b
genome). Reverse transcription (RT) was carried out with
0.2–1 g of RNA, 200 U superscript II reverse transcriptase
(Invitrogen, Catalog No. 18064-014), and 100 ng random
hexamer primers (Invitrogen, Catalog No. 48190-011) at
42°C for 50 min. cDNAs were then amplified with Pfu
Turbo DNA polymerase (Stratagene, Catalog No. 600252)
by 40 PCR cycles at 95°C for 30 s, 54°C for 30 s, and 72°C
for 2 min. The primers for NS5A were (forward) ATGTC-
CGGCTCGTGGCTAAGAG and (reverse) GCAGCA-
GACGACGTCCTCAC. The neo gene primers were (for-
ward) TCAAGACCGACCTGTCCGGTGCCC and (reverse)
CTTGAGCCTGGCGAACAGTTCGGC. PCR products
were then cloned into the pCR-Blunt II-TOPO vector (In-
vitrogen, Catalog No. K2800-20) and plasmid DNA from
independent colonies for each treatment (or no drug control)
was sequenced in both directions. Sequencing data were
analyzed with the Vector NTI program.
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